Skip to main content
. 2020 Jul 15;22(8):43. doi: 10.1007/s11883-020-00860-w

Fig. 4.

Fig. 4

Renal safety of pemafibrate. Estimated glomerular filtration rate (eGFR) (a) and serum creatinine (b) over 52 weeks showed favorable renal safety in patients with normal and impaired renal function, treated with pemafibrate (0.2–0.4 mg daily). Reproduced with permission from Yokote et al. [64•] under Creative Commons License 4.0 (https://creativecommons.org/licenses/by/4.0/)